Tempest Therapeutics (TPST) Stock: Buy, Sell, or Hold?
TPST - Tempest Therapeutics, Inc. Common Stock
$0.61
-0.01 (-1.54%)
▼
5d:
-17.25%
30d:
-36.51%
90d:
-37.93%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 04, 2026
15d
Get Alerted When TPST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TPST is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TPST is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TPST is currently trading at $0.61, which is considered oversold relative to its 30-day fair value range of $0.68 to $0.93.
Technical Outlook: Technically, TPST is in a downtrend. The price is currently testing key support at $0.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TPST scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+1021.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TPST is in a downtrend. The price is currently testing key support at $0.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TPST scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+1021.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.68 -
$0.93
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1021.4% below Wall St target ($7.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.68 -
$0.93
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$0.83
Current Trend
Downtrend
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.69
Wall Street Target
$7.00
(+1021.4%)
Share & Embed Analysis
Last updated: October 19, 2026 10:48 AM ET
Data refreshes hourly during market hours. Next update: 11:48 AM
Data refreshes hourly during market hours. Next update: 11:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TPST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 64 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 63 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 55 HOLD |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$120 | 55 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 46 HOLD |
